Have Plaintiffs Found the Zoloft’s Smoking Gun

New York, New York – Case Funding a Division of Javlin Capital  June 8th , 2015

Zoloft is in the news again and this time it isn’t in Pfizer’s favor.  According to Bloomberg “A Pfizer Inc. report shows a scientist warned executives last year about a potential link between the anti-depressant drug Zoloft and birth defects and recommended changes to the medication’s safety warning.” This document was not used in the MDL case in April, and could very well change the landscape of the MDL overall.

While a single document doesn’t necessarily change the entire outcome of an MDL, this certainly helps the plaintiffs. A document by an internal staff member advising executives that there may be dangers other than those listed, could in fact be the smoking gun attorneys were looking for. The general public and those with vested interest in Zoloft will have to wait and see how a judge and jury interpret this “smoking gun”.

If you are an attorney who handles Zoloft cases or an individual who has taken Zoloft and been injured by it. Case Funding offers financing to attorneys as well as individuals harmed by Zoloft, to find out more about what Case Funding offers please call us at (800) 543-4043.

The NFL Settlement Appeal and What it Means.

New York, New York – Case Funding a Division of Javlin Capital May 26, 2015 Many NFL retirees believed their long awaited settlements were in clear site, but now, the fog of appeal has obscured their vision. That fog is … Continue reading

Bayer is Bullish on Xarelto

New York – New York Bayer is Bullish on Xarelto despite MDL’s growing in America according to this Reuters article. Claims were circulating that the drug maker was losing market share to Eliquis but the contrary is being claimed by Bayer. … Continue reading

Actos, the not so safe alternative for type 2 diabetes

Approximately 9000 claimants breathed a sigh relief this past week. Takeda, the Japanese pharmaceutical giant agreed to settle approximately 9000 cases for a total of $2.4 billion. This translates roughly to $267,000 per case. The decline of use and eventual … Continue reading